| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2012-07-11 | BI-204 | atherosclerosis and acute coronary syndromes | 2a | Bioinvent International (Sweden) Genentech a member of the Roche Group (USA-Switzerland) | Cardiovascular diseases |
| 2012-07-10 | IB1001 (recombinant factor IX) | hemophilia B | 3 | Inspiration Biopharmaceuticals (USA) Ipsen (France) | Hematological diseases - Genetic diseases |
| 2012-07-09 | solulin | treatment and prevention of radiation injury | preclinical | Paion (Germany) | Cancer - Oncology |
| 2012-07-05 | Erbitux® (cetuximab) | advanced gastric adenocarcinoma including adenocarcinoma of the gastro-esophageal junction (GEJ) |
3 | Merck Serono, a Merck KGaA company (Germany) | Cancer - Oncology |
| 2012-07-05 | OMP-18R5 (vantictumab) | preclinical data | Oncomed Pharmaceuticals (USA) Morphosys (Germany) | Cancer - Oncology | |
| 2012-07-03 | NP2 Enkephalin | cancer pain | 2 | Diamyd Medical (Sweden) | Cancer - Oncology - CNS diseases |
| 2012-07-02 | investigational combination LAMA/LABA (GSK573719 and vilanterol) | chronic obstructive pulmonary disease (COPD) | 3 | GSK (UK) Theravance (USA) | Respiratory diseases |
| 2012-07-02 | combined treatment with albumin plasmapheresis and intravenous immunoglobulin (IVIG) at different doses | Alzheimer\'s disease | Grifols (Spain) | Neurodegenerative diseases | |
| 2012-06-29 | lipegfilgrastim | reduction of the duration of severe neutropenia in breast cancer patients undergoing chemotherapy | 3 | Teva Pharmaceutical Industries (Israel) | Cancer - Oncology |
| 2012-06-29 | balugrastim (recombinant G-CSF fused to human albumin) | reduction in the duration of severe neutropenia in breast cancer patients undergoing chemotherapy | 3 | Teva Pharmaceutical Industries (Israel) | Cancer - Oncology |
| 2012-06-29 | SEL103 program | Alzheimer’s disease | Selvita (Poland) Orion (Finland) | Neurodegenerative diseases | |
| 2012-06-29 | belinostat | carcinoma of unknown primary (CUP) |
2 | Topotarget (Denmark) | Cancer - Oncology |
| 2012-06-28 | Vpriv® (velaglucerase alfa) | Gaucher disease |
3 | Shire (UK-USA) | Rare diseases |
| 2012-06-25 | ozoralizumab | rheumatoid arthritis |
2 | Pfizer (USA - NY) Ablynx (Belgium) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2012-06-25 | IFN-alpha-2b XL | chronic hepatitis C | 2 | Flamel Technologies (France) | Infectious diseases |
| 2012-06-19 | AZD2820 | obesity | 1 | AstraZeneca (UK) Palatin Technologies (USA) | Metabolic diseases |
| 2012-06-19 | Kappaproct® | refractory ulcerative colitis | InDex Pharmaceuticals (Sweden) | Inflammatory diseases - Autoimmune diseases | |
| 2012-06-18 | Ruconest® (Rhucin® in non european countries - conestat alfa) | acute angioedema attacks in patients with hereditary angioedema (HAE) | 3 | Pharming (The Netherlands) | |
| 2012-06-18 | vidofludimus (4SC-101) | kidney transplantation |
preclinical | 4SC (Germany) | Transplantation |
| 2012-06-17 | erythrocyte encapsulated asparaginase | adult lymphoblastic leukemia (ALL) |
2 | Erytech Pharma (France) | Cancer - Oncology |
